Tumor-infiltrating Leukocyte Profiling Defines Three Immune Subtypes of NSCLC with Distinct Signaling Pathways and Genetic Alterations
Immune checkpoint
DOI:
10.1158/2767-9764.crc-22-0415
Publication Date:
2023-05-24T13:07:11Z
AUTHORS (41)
ABSTRACT
Resistance to immune checkpoint blockade remains challenging in patients with non-small cell lung cancer (NSCLC). Tumor-infiltrating leukocyte (TIL) quantity, composition, and activation status profoundly influence responsiveness immunotherapy. This study examined the landscape NSCLC tumor microenvironment by analyzing TIL profiles of 281 fresh resected tissues. Unsupervised clustering based on numbers percentages 30 types classified adenocarcinoma (LUAD) squamous carcinoma (LUSQ) into cold, myeloid cell-dominant, CD8+ T cell-dominant subtypes. These were significantly correlated patient prognosis; subtype had worse outcomes than others. Integrated genomic transcriptomic analyses, including RNA sequencing, whole-exome T-cell receptor repertoire, metabolomics tissue, revealed that reaction-related signaling pathways inactivated, while glycolysis K-ras activated LUAD LUSQ Cases ALK ROS1 fusion genes enriched subtype, frequency TERT copy-number variations was higher classifications may be useful for developing personalized therapies NSCLC.The precise profiling novel three subtypes correlates outcome, identifying subtype-specific molecular alterations should play important roles constructing microenvironments. are NSCLC.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (43)
CITATIONS (3)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....